FDA Greenlights Sanofi's Diabetes Treatment for Young Patients
The FDA has granted approval for a Sanofi diabetes medication aimed at children diagnosed with stage 3 diabetes, amid prior internal disputes.
Editorial Staff
1 min read
Updated about 9 hours ago
The FDA has officially approved a new diabetes drug from Sanofi that targets children suffering from stage 3 diabetes.
This approval comes after a notable dispute between career staff and the political appointee leading the Center for Drug Evaluation and Research (CDER).
The decision highlights ongoing tensions within the FDA regarding the approval processes for new medications.